Clinuvel Pharmaceuticals Limited
CLVLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 66.5% | -36.3% | 70.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 68.4% | 91.4% | 73.3% | 51.6% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 50.9% | 47.4% | 62.3% | 65.3% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 37.2% | 39.5% | 44.2% | 33.3% |
| EPS Diluted | 0.44 | 0.28 | 0.49 | 0.21 |
| % Growth | 57.1% | -42.9% | 133.3% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |